Llwytho...
Improving clinical trial design for Duchenne muscular dystrophy
BACKGROUND: Currently, the most promising therapies for Duchenne muscular dystrophy (DMD) are exon skipping and stop codon read-through, two strategies aimed at restoring the expression of dystrophin. A phase 3 clinical trial with drisapersen, a drug designed to induce exon 51-skipping, has failed t...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | BMC Neurol |
|---|---|
| Prif Awduron: | , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
BioMed Central
2015
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4549867/ https://ncbi.nlm.nih.gov/pubmed/26306629 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-015-0408-z |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|